TrialESMO open2023

Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18.

M Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.